RadioMedix

About

RadioMedix, Inc. is a clinical-stage biotechnology company based in Houston, Texas, specializing in the development and commercialization of cutting-edge radiopharmaceutical oncology solutions. The company focuses on targeted alpha and beta therapies alongside next-generation diagnostic imaging agents, positioning itself at the forefront of precision cancer treatment and diagnosis. RadioMedix demonstrates exceptional expertise in critical isotopes including Ac-225, Lu-177, Pb-212, Pb-203, and Ga-68, enabling comprehensive radiopharmaceutical development from early-stage research through commercial-scale Good Manufacturing Practice (GMP) production. The company operates as both an innovator and Contract Development and Manufacturing Organization (CDMO), offering partnership opportunities for pharmaceutical companies seeking specialized radiopharmaceutical manufacturing capabilities. The Houston-based facility combines advanced manufacturing infrastructure with rigorous quality standards, supporting the growing demand for targeted cancer therapies. RadioMedix's comprehensive approach spans the entire radiopharmaceutical lifecycle, from initial research and development to full-scale commercial manufacturing, making it a valuable partner in the oncology pharmaceutical sector. With locations on Richmond Avenue and at the Spica Center in Humble, Texas, RadioMedix is strategically positioned to serve both domestic and international markets. The company's mission centers on creating paradigm shifts in cancer diagnosis and treatment through innovative radiopharmaceutical solutions that improve patient outcomes.